News »Agilvax to Showcase Data During AACR 2017 Annual Meeting in Washington, DC

Albuquerque, NM

March 31, 2017

Albuquerque, NM, March 31, 2017. Agilvax, Inc., a biotechnology company that is developing novel cancer stem cell targeting immunotherapies, announced today that Dr. John O’Rourke, Director of Oncology, will be presenting a poster, AX09: An Immunotherapy Candidate Targeting the Breast Cancer Stem Cell Protein xCT, at the American Association for Cancer Research (AACR) Annual Meeting to be held in Washington, DC, April 1-5, 2017. Additionally, Agilvax’s key collaborator, Dr. Federica Cavallo, from the University of Turin will be presenting data during her presentation, The cystine/glutamate antitporter (xCT): A new cancer stem cell target for anticancer vaccines.


Session Category: Immunology
Session Title: Enzymes and Hormones and Metabolism in Tumor Immunity
Date and Time: Wednesday Apr 5, 2017 8:00 AM - 12:00 PM
Location: Convention Center, Halls A-C, Poster Section 24
Poster Board No: 4
Poster Title: AX09: An Immunotherapy Candidate Targeting the Breast Cancer Stem Cell Protein xCT


Session Type: Recent Advances in Prevention Research
Session Title: Premalignant Lesions as Targets for Immunoprevention
Session Start Time: Tuesday, April 4, 2017, 1:00 PM
Session End Time: Tuesday, April 4, 2017, 2:45 PM
Location: Ballroom C, Level 3, Washington Convention Center
CME Status: CME-Designated Session
Presentation Title: The cystine/glutamate antiporter (xCT): A new cancer stem cell target for anticancer vaccines

About Agilvax

Agilvax ( is a biotechnology company that develops innovative cancer therapeutics and vaccines using its proven virus-like particle (VLP) platform technology. Agilvax’s lead immunotherapy product, AX09, is intended for the treatment of triple-negative breast cancer (TNBC). The Company is also developing vaccines against infectious diseases with a high unmet clinical need, such as respiratory syncytial virus (RSV). Agilvax has a solid intellectual property portfolio covering products (composition of matter and method of use) and the discovery platform. The Company was formed in 2011 and has raised just over $4 million in equity investment (Series A). The Company has also secured collaborations with government (NIH) and several pharmaceutical partners (Leidos, Integrated Biotherapeutics, Humabs Biomed). Agilvax is headquartered in Albuquerque, NM with offices in El Paso, TX.

Back to News